Neuroscience
From Pharmalot blog, a good read about the Amyvid approval decision:
Should FDA Have Approved Lilly Alzheimer’s Agent?
Pharmalot
By Ed Silverman
April 9th, 2012 // 11:23 am
Read the full blog post
- Alzheimer's Disease: A Wrap For Bap
Trials for Alzheimer’s Drug Halted After Poor Results By KATIE THOMAS The New York Times 06 August 2012 Read full article ---Corporate Press Release: Read the releaseCommentary from the In The Pipeline blog: In The PipelineCommentary from Pharmalot:...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Clinical Trials: Moscow Rules
An interesting posting on the Pharmalot blog today: Russian Trial Rules Are A ‘Serious Blow’ To Pharma By Ed Silverman November 29th, 2011 // 9:56 am Read the blog post...
- Pharmalot Interview With Dr. Michael Rogawski About Reporting Data In Clinical Trials
A fine read from the Pharmalot blog: All Trial Data Must Be Disclosed: Rogawski Explains By Ed Silverman October 5th, 2011 - 9:36 am Read the full blog posting...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
Neuroscience
Amyvid Approval
From Pharmalot blog, a good read about the Amyvid approval decision:
Should FDA Have Approved Lilly Alzheimer’s Agent?
Pharmalot
By Ed Silverman
April 9th, 2012 // 11:23 am
Read the full blog post
- Alzheimer's Disease: A Wrap For Bap
Trials for Alzheimer’s Drug Halted After Poor Results By KATIE THOMAS The New York Times 06 August 2012 Read full article ---Corporate Press Release: Read the releaseCommentary from the In The Pipeline blog: In The PipelineCommentary from Pharmalot:...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Clinical Trials: Moscow Rules
An interesting posting on the Pharmalot blog today: Russian Trial Rules Are A ‘Serious Blow’ To Pharma By Ed Silverman November 29th, 2011 // 9:56 am Read the blog post...
- Pharmalot Interview With Dr. Michael Rogawski About Reporting Data In Clinical Trials
A fine read from the Pharmalot blog: All Trial Data Must Be Disclosed: Rogawski Explains By Ed Silverman October 5th, 2011 - 9:36 am Read the full blog posting...
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...